NCT07036250 - Clinical Study of U32 in Patients With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Acute Myeloid Leukaemia

Interventions

DRUG

U32 CAR-T

Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou, JiangSu 215000 Recruiting, Suzhou

All Listed Sponsors

lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY